Free daily briefing on global business news.
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Bristol Myers Squibb $BMY BMY announced positive phase II results from the registrational QUINTESSENTIAL study evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in heavily pretreated patients with relapsed and refractory multiple myeloma.
Arlo-cel is a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CAR T cell therapy.
The results are encouraging because arlo-cel targets GPRC5D, giving BMY an opportunity to treat patients already exposed to BCMA-directed therapies. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) in quadruple-class exposed patients who had received at least four prior lines of therapy. The trial also met key secondary endpoints, including complete response rate (CRR), as well as ORR and CRR in patients who had received three or more prior lines of treatment.
